Trial Profile
Pharmacokinetics and Tolerability of Telavancin at Differing Dosing Regimens in Cystic Fibrosis Adults Admitted With Acute Pulmonary Exacerbations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Telavancin (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- 04 Nov 2019 Results (n=18) assessing pharmacokinetics of Telavancin in adult patients with cystic fibrosis published in the Antimicrobial Agents and Chemotherapy
- 05 Aug 2019 Status changed from recruiting to completed.
- 27 Apr 2018 Planned End Date changed from 30 Jun 2018 to 30 Jun 2019.